دورية أكاديمية
1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
| العنوان: | 1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial |
|---|---|
| المؤلفون: | Ruiz Vico, M., Wetterskog, D., Thakali, S., Orlando, F., Jayaram, A.K., Vainauskas, O., Castellano Gauna, D.E., Martins, K.D., Iwata, K., Gourgioti, G., Serikoff, A., Astrom, L., Matveev, V., Esen, A.A., Feyerabend, S., Senkus-Konefka, E., Gupta, S., Merseburger, A.S., Demichelis, F., Attard, G. |
| المصدر: | Annals of Oncology ; volume 34, page S994 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2023 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| مصطلحات موضوعية: | Oncology, Hematology |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.annonc.2023.09.2784 |
| الإتاحة: | https://doi.org/10.1016/j.annonc.2023.09.2784Test https://api.elsevier.com/content/article/PII:S0923753423036219?httpAccept=text/xmlTest https://api.elsevier.com/content/article/PII:S0923753423036219?httpAccept=text/plainTest |
| حقوق: | https://www.elsevier.com/tdm/userlicense/1.0Test/ |
| رقم الانضمام: | edsbas.AEA232F0 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2023.09.2784 |
|---|